Salicylaldehyde isonicotinoyl hydrazone (SIH) is a lipophilic, tridentate iron chelator with marked anti-oxidant and modest cytotoxic activity against neoplastic cells. However, it has poor stability in an aqueous environment due to the rapid hydrolysis of its hydrazone bond. In this study, we synthesized a series of new SIH analogs (based on previously described aromatic ketones with improved hydrolytic stability). Their structure-activity relationships were assessed with respect to their stability in plasma, iron chelation efficacy, redox effects and cytotoxic activity against MCF-7 breast adenocarcinoma cells. Furthermore, studies assessed the cytotoxicity of these chelators and their ability to afford protection against hydrogen peroxide-induced oxidative injury in H9c2 cardiomyoblasts. The ligands with a reduced hydrazone bond, or the presence of bulky alkyl substituents near the hydrazone bond, showed severely limited biological activity. The introduction of a bromine substituent increased ligand-induced cytotoxicity to both cancer cells and H9c2 cardiomyoblasts. A similar effect was observed when the phenolic ring was exchanged with pyridine (i.e., changing the ligating site from O, N, O to N, N, O), which led to pro-oxidative effects. In contrast, compounds with long, flexible alkyl chains adjacent to the hydrazone bond exhibited specific cytotoxic effects against MCF-7 breast adenocarcinoma cells and low toxicity against H9c2 cardiomyoblasts. Hence, this study highlights important structure-activity relationships and provides insight into the further development of aroylhydrazone iron chelators with more potent and selective anti-neoplastic effects.

Charles University Prague Faculty of Pharmacy in Hradec Králové Hradec Králové Czech Republic

Molecular Pharmacology and Pathology Program Bosch Institute and Department of Pathology University of Sydney Sydney Australia

See more in PubMed

Wang J, Pantopoulos K (2011) Regulation of cellular iron metabolism. Biochem J 434: 365–381. PubMed PMC

Lawen A, Lane DJ (2013) Mammalian iron homeostasis in health and disease: uptake, storage, transport, and molecular mechanisms of action. Antioxid Redox Signal 18: 2473–2507. PubMed

Dunn LL, Suryo Rahmanto Y, Richardson DR (2007) Iron uptake and metabolism in the new millennium. Trends Cell Biol 17: 93–100. PubMed

Hentze MW, Muckenthaler MU, Andrews NC (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117: 285–297. PubMed

Richardson DR, Baker E (1991) The release of iron and transferrin from the human melanoma cell. Biochim Biophys Acta 1091: 294–302. PubMed

Napier I, Ponka P, Richardson DR (2005) Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood 105: 1867–1874. PubMed

Richardson DR, Lane DJ, Becker EM, Huang ML, Whitnall M, et al. (2010) Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci U S A 107: 10775–10782. PubMed PMC

Arredondo M, Nunez MT (2005) Iron and copper metabolism. Mol Aspects Med 26: 313–327. PubMed

Leidgens S, Bullough KZ, Shi H, Li F, Shakoury-Elizeh M, et al. (2013) Each member of the poly-r(C)-binding protein 1 (PCBP) family exhibits iron chaperone activity toward ferritin. J Biol Chem 288: 17791–17802. PubMed PMC

Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, et al. (1996) The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 271: 20291–20299. PubMed

Lane DJ, Mills TM, Shafie NH, Merlot AM, Saleh Moussa R, et al. (2014) Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial-mesenchymal transition. Biochim Biophys Acta 1845: 166–181. PubMed

Kalinowski DS, Richardson DR (2005) The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57: 547–583. PubMed

Merlot AM, Kalinowski DS, Richardson DR (2013) Novel chelators for cancer treatment: where are we now? Antioxid Redox Signal 18: 973–1006. PubMed

Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB (2009) Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta 1790: 702–717. PubMed

Bendova P, Mackova E, Haskova P, Vavrova A, Jirkovsky E, et al. (2010) Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol 23: 1105–1114. PubMed

Torti SV, Torti FM (2013) Iron and cancer: more ore to be mined. Nat Rev Cancer 13: 342–355. PubMed PMC

Kolberg M, Strand KR, Graff P, Andersson KK (2004) Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta 1699: 1–34. PubMed

Walker RA, Day SJ (1986) Transferrin receptor expression in non-malignant and malignant human breast tissue. J Pathol 148: 217–224. PubMed

Jiang XP, Elliott RL, Head JF (2010) Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas. Anticancer Res 30: 759–765. PubMed

Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, et al. (2010) Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2: 43ra56. PubMed PMC

Le NT, Richardson DR (2002) The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 1603: 31–46. PubMed

Whitnall M, Howard J, Ponka P, Richardson DR (2006) A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 103: 14901–14906. PubMed PMC

Lovejoy DB, Sharp DM, Seebacher N, Obeidy P, Prichard T, et al. (2012) Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J Med Chem 55: 7230–7244. PubMed

Vitolo LMW, Hefter GT, Clare BW, Webb J (1990) Iron Chelators of the Pyridoxal Isonicotinoyl Hydrazone Class.2. Formation-Constants with Iron(Iii) and Iron(Ii). Inorganica Chimica Acta 170: 171–176.

Dubois JE, Fakhrayan H, Doucet JP, Chahine JME (1992) Kinetic and Thermodynamic Study of Complex-Formation between Iron(Ii) and Pyridoxal Isonicotinoylhydrazone and Other Synthetic Chelating-Agents. Inorganic Chemistry 31: 853–859.

Horackova M, Ponka P, Byczko Z (2000) The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H(2)O(2) injury in adult cardiomyocytes. Cardiovasc Res 47: 529–536. PubMed

Simunek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AM, et al. (2005) SIH–a novel lipophilic iron chelator–protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J Mol Cell Cardiol 39: 345–354. PubMed

Simunek T, Sterba M, Popelova O, Kaiserova H, Adamcova M, et al. (2008) Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. Br J Pharmacol 155: 138–148. PubMed PMC

Berndt C, Kurz T, Selenius M, Fernandes AP, Edgren MR, et al. (2010) Chelation of lysosomal iron protects against ionizing radiation. Biochem J 432: 295–301. PubMed

Fillebeen C, Pantopoulos K (2010) Iron inhibits replication of infectious hepatitis C virus in permissive Huh7.5.1 cells. J Hepatol 53: 995–999. PubMed

Mackova E, Hruskova K, Bendova P, Vavrova A, Jansova H, et al. (2012) Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action. Chem Biol Interact 197: 69–79. PubMed

Klimtova I, Simunek T, Mazurova Y, Kaplanova J, Sterba M, et al. (2003) A study of potential toxic effects after repeated 10-week administration of a new iron chelator—salicylaldehyde isonicotinoyl hydrazone (SIH) to rabbits. Acta Medica (Hradec Kralove) 46: 163–170. PubMed

Hruskova K, Kovarikova P, Bendova P, Haskova P, Mackova E, et al. (2011) Synthesis and initial in vitro evaluations of novel antioxidant aroylhydrazone iron chelators with increased stability against plasma hydrolysis. Chem Res Toxicol 24: 290–302. PubMed

Richardson DR, Tran EH, Ponka P (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86: 4295–4306. PubMed

Chaston TB, Lovejoy DB, Watts RN, Richardson DR (2003) Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 9: 402–414. PubMed

Chaston TB, Richardson DR (2003) Redox chemistry and DNA interactions of the 2-pyridyl-carboxaldehyde isonicotinoyl hydrazone class of iron chelators: Implications for toxicity in the treatment of iron overload disease. J Biol Inorg Chem 8: 427–438. PubMed

Becker EM, Lovejoy DB, Greer JM, Watts R, Richardson DR (2003) Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Br J Pharmacol 138: 819–830. PubMed PMC

Richardson DR, Ponka P (1994) The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J Lab Clin Med 124: 660–671. PubMed

Edward JT, Gauthier M, Chubb FL, Ponka P (1988) Synthesis of New Acylhydrazones as Iron-Chelating Compounds. Journal of Chemical and Engineering Data 33: 538–540.

Administration FaD (2001) Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf. Accessed 2014 September 15.

Kovarikova P, Mrkvickova Z, Klimes J (2008) Investigation of the stability of aromatic hydrazones in plasma and related biological material. J Pharm Biomed Anal 47: 360–370. PubMed

Esposito BP, Epsztejn S, Breuer W, Cabantchik ZI (2002) A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal Biochem 304: 1–18. PubMed

Glickstein H, El RB, Link G, Breuer W, Konijn AM, et al. (2006) Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Blood 108: 3195–3203. PubMed

Richardson DR, Milnes K (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 89: 3025–3038. PubMed

Baker E, Richardson D, Gross S, Ponka P (1992) Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 15: 492–501. PubMed

Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, et al. (2006) Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem 49: 6510–6521. PubMed

Becker E, Richardson DR (1999) Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J Lab Clin Med 134: 510–521. PubMed

Mladenka P, Kalinowski DS, Haskova P, Bobrovova Z, Hrdina R, et al. (2009) The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity. Chem Res Toxicol 22: 208–217. PubMed

Chaston TB, Watts RN, Yuan J, Richardson DR (2004) Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation. Clin Cancer Res 10: 7365–7374. PubMed

Repetto G, del Peso A, Zurita JL (2008) Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 3: 1125–1131. PubMed

Ghose AK, Crippen GM (1987) Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions. J Chem Inf Comput Sci 27: 21–35. PubMed

Viswanadhan VN, Ghose AK, Revankar GR, Robins RK (1989) Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 29: 163–172.

Broto P, Moreau G, Vandycke C (1984) Molecular Structures: Perception, Autocorrelation Descriptor and SAR Studies. System of Atomic Contributions for the Calculation of the n-Octanol/Water Partition Coefficients. Eur J Med Chem Chim Theor 19: 71–78.

Zhang XZ, Li M, Cui Y, Zhao J, Cui ZG, et al. (2012) Electrochemical Behavior of Calcein and the Interaction Between Calcein and DNA. Electroanalysis 24: 1878–1886.

Yuan J, Lovejoy DB, Richardson DR (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104: 1450–1458. PubMed

Gutteridge JM, Richmond R, Halliwell B (1979) Inhibition of the iron-catalysed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamine. Biochem J 184: 469–472. PubMed PMC

Ponka P, Borova J, Neuwirt J, Fuchs O (1979) Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 97: 317–321. PubMed

Kalia J, Raines RT (2008) Hydrolytic stability of hydrazones and oximes. Angew Chem Int Ed Engl 47: 7523–7526. PubMed PMC

Kitazawa M, Iwasaki K (1999) Reduction of ultraviolet light-induced oxidative stress by amino acid-based iron chelators. Biochim Biophys Acta 1473: 400–408. PubMed

Bernhardt PV, Wilson GJ, Sharpe PC, Kalinowski DS, Richardson DR (2008) Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands. J Biol Inorg Chem 13: 107–119. PubMed

Sies H (1993) Strategies of antioxidant defense. Eur J Biochem 215: 213–219. PubMed

Richardson D, Vitolo LW, Baker E, Webb J (1989) Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acidic, neutral and basic aqueous solutions by ultraviolet-visible spectrophotometry. Biol Met 2: 69–76. PubMed

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents